Given the essential role of the JAK1/2 pathway in the efficacy of PD-L1 blockade therapy, we conducted further investigations to explore its potential influence on how PD-L1 blockade therapy affects the tumor vascular structures. This evidence concerns the gene JAK1 and neoplasm.